Last hope? new combo targets liver cancer that beat previous treatments

NCT ID NCT07639138

Recruiting now Disease control Sponsor: Shunda Du Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug lenalidomide to ongoing targeted therapy and immunotherapy can help people with advanced liver cancer whose disease has worsened after multiple prior treatments. About 32 participants will receive the combination and be monitored for tumor response and side effects. The goal is to see if this approach can slow cancer growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide
What this could lead to: If successful, this could offer a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 32 participants, so results may not apply widely. Adding lenalidomide may increase side effects like low blood counts or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.